Biogen Inc.

NasdaqGS:BIIB

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 18.51 B

Share Price

USD 126.31

Avg Daily Volume

1,772,992

Change (1 day)

1.24%

Change (1 year)

-44.26%

Change (YTD)

-17.40%

Biogen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 9.82 B

Biogen Inc. Revenue is USD 9.82 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 1.59% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Biogen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 9.66 B, a -4.37% change year over year.
Biogen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 10.10 B, a -6.61% change year over year.
Biogen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 10.82 B, a -14.16% change year over year.
Biogen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 12.60 B, a -12.61% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqGS: BIIB

Biogen Inc.

CEO	Mr. Christopher A. Viehbacher
IPO Date	Sept. 17, 1991
Location	United States
Headquarters	225 Binney Street
Employees	7,605
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.